NEOGENOMICS INC
For the period ended Dec 31, 2025. Filed Feb 17, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 17, 2026
NEO$16.96-3.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Financial Statements and Supplementary Data
| Table of Contents | NEOGENOMICS, INC. |
|---|
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Page | |
|---|---|
| Report of Independent Registered Public Accounting Firm – Deloitte & Touche LLP (PCAOB ID: 34) | 58 |
| Consolidated Balance Sheets as of December 31, 2025 and 2024 | 61 |
| Consolidated Statements of Operations for the years ended December 31, 2025, 2024 and 2023 | 62 |
| Consolidated Statements of Comprehensive Loss for the years ended December 31, 2025, 2024 and 2023 | 63 |
| Consolidated Statements of Stockholders’ Equity for the years ended December 31, 2025, 2024 and 2023 | 64 |
| Consolidated Statements of Cash Flows for the years ended December 31, 2025, 2024 and 2023 | 65 |
| Notes to Consolidated Financial Statements | 67 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.